Atroshi Isam, Nordenskjöld Jesper, Lauritzson Anna, Ahlgren Eva, Waldau Johanna, Waldén Markus
Department of Orthopedics, Hässleholm, Kristianstad, and Ystad Hospitals , Hässleholm ;
Acta Orthop. 2015 Jun;86(3):310-5. doi: 10.3109/17453674.2015.1019782. Epub 2015 Feb 19.
Treatment of Dupuytren's contracture (DC) with collagenase Clostridium histolyticum (CCH) consists of injection followed by finger manipulation. We used a modified method, injecting a higher dose than recommended on the label into several parts of the cord, which allows treatment of multiple joint contractures in 1 session and may increase efficacy. We studied the occurrence of skin tears and short-term outcome with this procedure.
We studied 164 consecutive hands with DC, palpable cord, and extension deficit of ≥ 20º in the metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joint (mean patient age 70 years, 82% men). A hand surgeon injected all the content of 1 CCH vial (approximately 0.80 mg) into multiple spots in the cord and performed finger extension under local anesthesia after 1 or 2 days. A nurse recorded skin tears on a diagram and conducted a standard telephone follow-up within 4 weeks. A hand therapist measured joint contracture before injection and at a median of 23 (IQR: 7-34) days after finger extension.
A skin tear occurred in 66 hands (40%). The largest diameter of the tear was ≤ 5 mm in 30 hands and > 10 mm in 14 hands. Hands with skin tear had greater mean pretreatment MCP extension deficit than those without tear: 59º (SD 26) as opposed to 32º (SD 23). Skin tear occurred in 21 of 24 hands with MCP contracture of ≥ 75º. All tears healed with open-wound treatment. No infections occurred. Mean improvement in total (MCP + PIP) extension deficit was 55º (SD 28).
Skin tears occurred in 40% of hands treated with collagenase injections, but only a fifth of them were larger than 1 cm. Tears were more likely in hands with severe MCP joint contracture. All tears healed without complications. Short-term contracture reduction was good.
使用溶组织梭状芽孢杆菌胶原酶(CCH)治疗掌腱膜挛缩症(DC)包括注射及后续手指手法操作。我们采用了一种改良方法,即在条索的多个部位注射高于标签推荐剂量的药物,这使得在一次治疗中就能处理多个关节挛缩,且可能提高疗效。我们研究了该操作中皮肤撕裂的发生率及短期疗效。
我们研究了164例连续的患有DC、可触及条索且掌指(MCP)和/或近端指间(PIP)关节伸展受限≥20°的手部病例(患者平均年龄70岁,82%为男性)。一名手外科医生将1瓶CCH的全部内容物(约0.80mg)注射到条索的多个部位,并在1或2天后在局部麻醉下进行手指伸展操作。一名护士在图表上记录皮肤撕裂情况,并在4周内进行标准的电话随访。一名手部治疗师在注射前及手指伸展后中位数为23天(四分位间距:7 - 34天)时测量关节挛缩情况。
66只手(40%)出现皮肤撕裂。撕裂的最大直径在30只手中≤5mm,在14只手中>10mm。有皮肤撕裂的手在治疗前MCP平均伸展受限程度比无撕裂的手更大:分别为59°(标准差26)和32°(标准差23)。在24只MCP挛缩≥75°的手中,有21只出现皮肤撕裂。所有撕裂通过开放伤口处理均愈合。未发生感染。总(MCP + PIP)伸展受限平均改善55°(标准差28)。
用胶原酶注射治疗的手部中,40%出现皮肤撕裂,但其中只有五分之一大于1cm。在MCP关节严重挛缩的手中更易出现撕裂。所有撕裂均愈合且无并发症。短期挛缩减轻效果良好。